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Abstract
Background: The	 ‘Prediction	 Of	 Survival	 in	 Advanced	 Sorafenib‐treated	 HCC’	
(PROSASH)	model	addressed	the	heterogeneous	survival	of	patients	with	hepatocel‐
lular	carcinoma	(HCC)	treated	with	sorafenib	in	clinical	trials	but	requires	validation	in	
daily	clinical	practice.	This	study	aimed	to	validate,	compare	and	optimize	this	model	
for	survival	prediction.
Methods: Patients	treated	with	sorafenib	for	HCC	at	five	tertiary	European	centres	
were	retrospectively	staged	according	to	the	PROSASH	model.	In	addition,	the	opti‐
mized	PROSASH‐II	model	was	developed	using	the	data	of	four	centres	(training	set)	
This	is	an	open	access	article	under	the	terms	of	the	Creat	ive	Commo	ns	Attri	bution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
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1  | INTRODUC TION
Hepatocellular	carcinoma	(HCC)	 is	the	most	common	primary	 liver	
cancer	and	the	second	leading	cause	of	cancer‐related	death	world‐
wide.1	Most	patients	with	HCC	present	with,	or	eventually	progress	
to,	advanced	stage	disease	which	bears	a	poor	prognosis.	Sorafenib,	
a	multikinase	 inhibitor,	was	 the	 first	 treatment	 to	 show	a	 survival	
benefit	 in	patients	with	advanced	stage	HCC.	 In	 two	 randomized‐
controlled	trials,	sorafenib	improved	the	median	overall	survival	(OS)	
by	2‐3	months	compared	with	placebo.2,3	Since	then,	sorafenib	has	
been	the	standard	treatment	for	patients	with	advanced	stage	HCC	
who	are	 ineligible	 for	 loco‐regional	 treatment	and	have	preserved	
(Child‐Pugh	A)	liver	function.
However,	 there	 is	 significant	heterogeneity	 in	outcomes	 in	pa‐
tient	 treated	 with	 sorafenib	 with	 an	 OS	 ranging	 from	 <3	 months	
to	2‐3	years.2‐4	This	 indicates	 that	 the	 survival	 benefit	 offered	by	
sorafenib	varies	between	individual	patients.	Select	subgroups	may	
have	similar	or	more	benefit	from	alternative	options	such	as	lenva‐
tinib,5	best	supportive	care	or	clinical	trials.
The	variety	 in	survival	 is	 inadequately	captured	by	 the	currently	
available	 staging	 systems	 (ie	 Barcelona	 Clinic	 Liver	 Cancer	 [BCLC]).	
Therefore,	guidelines	have	recommended	exploration	of	further	strat‐
ification	of	patients	with	 intermediate	 (BCLC‐B)	and	advanced	stage	
HCC	(BCLC‐C).6	Previous	studies	have	identified	markers	of	liver	func‐
tion	(ie	albumin,	bilirubin),	clinical	parameters	(ie	performance	status,	
body	composition)	and	 tumour	characteristics	 (ie	alpha‐foetoprotein	
[AFP],	macrovascular	 invasion,	 tumour	extent)	 that	may	aid	 in	prog‐
nostic	stratification	prior	to	sorafenib	treatment.7‐15	Predictive	factors,	
that	is,	those	associated	with	improved	survival	benefit	over	placebo,	
included	absence	of	extrahepatic	spread,	presence	of	hepatitis	C	virus	
and	a	low	neutrophil‐to‐lymphocyte	ratio	(NLR).16	Based	on	the	combi‐
nation	of	baseline	factors,	several	scoring	systems	have	been	proposed	
for	survival	stratification	of	patients	with	advanced	HCC	treated	with	
sorafenib.17‐20	Limitations	of	these	models	include	the	use	of	factors	
that	either	have	a	degree	of	subjectivity	(ie	infiltrative	tumour	growth,	
ascites)	 or	 are	 not	 commonly	 available	 (ie	 Des‐gamma‐carboxypro‐
thrombin	 [DCP]).	 A	 recently	 proposed	 model,	 the	 ‘Prediction	 Of	
Survival	in	Advanced	Sorafenib‐treated	HCC’	(PROSASH),	provided	in‐
dividualized	survival	prediction	with	excellent	risk	group	discrimination	
based	on	nine	parameters	(age,	macrovascular	invasion,	extrahepatic	
spread,	performance	status,	disease	aetiology,	albumin,	creatinine,	as‐
partate	transaminase	(AST)	and	AFP).21	The	PROSASH	model	was	built	
and	validated	on	the	data	from	patients	treated	with	sorafenib	in	two	
and	tested	 in	an	 independent	dataset.	These	models	 for	overall	 survival	 (OS)	were	
then	compared	with	existing	prognostic	models.
Results: The	PROSASH	model	was	validated	 in	445	patients,	 showing	clear	differ‐
ences	between	 the	 four	 risk	groups	 (OS	16.9‐4.6	months).	A	 total	of	920	patients	
(n	=	615	in	training	set,	n	=	305	in	validation	set)	were	available	to	develop	PROSASH‐
II.	 This	 optimized	 model	 incorporated	 fewer	 and	 less	 subjective	 parameters:	 the	
serum	albumin,	bilirubin	and	alpha‐foetoprotein,	and	macrovascular	invasion,	extra‐
hepatic	spread	and	largest	tumour	size	on	imaging.	Both	PROSASH	and	PROSASH‐II	
showed	improved	discrimination	(C‐index	0.62	and	0.63,	respectively)	compared	with	
existing	prognostic	scores	(C‐index	≤0.59).	
Conclusions: In	HCC	patients	treated	with	sorafenib,	individualized	prediction	of	sur‐
vival	and	risk	group	stratification	using	baseline	prognostic	and	predictive	parameters	
with	the	PROSASH	model	was	validated.	The	refined	PROSASH‐II	model	performed	
at	least	as	good	with	fewer	and	more	objective	parameters.	PROSASH‐II	can	be	used	
as	a	tool	for	tailored	treatment	of	HCC	in	daily	practice	and	to	define	pre‐planned	
subgroups	for	future	studies.
K E Y W O R D S
hepatocellular	carcinoma,	model,	prediction,	prognosis,	sorafenib,	survival
Key Points
•	 Patients	with	incurable	liver	cancer	(hepatocellular	car‐
cinoma)	can	be	 treated	with	sorafenib	 to	expand	 their	
life	expectancy,	but	the	prognosis	with	this	drug	varies	
between	patients.
•	 In	 this	 large	 international	study,	we	tested	and	further	
improved	 a	 statistical	method	 that	 allows	 clinicians	 to	
estimate	the	survival	chances	of	an	individual	patient.
•	 This	 facilitates	 the	 communication	 with	 the	 patient	
when	 considering	 this	 treatment	 and	will	 help	 further	
research	to	find	better	drugs.
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clinical trials,22,23	but	has	not	yet	been	validated	in	patients	treated	in	
routine	clinical	practice.	Multiple	studies	in	various	tumour	types	have	
underlined	the	limited	applicability	of	data	from	the	strictly	selected	
and	homogeneous	patients	 treated	 in	clinical	 trials	 to	 the	more	het‐
erogeneous	population	in	routine	clinical	practice.24‐28	Moreover,	the	
PROSASH	model	has	not	yet	been	compared	with	 the	currently	ex‐
isting	prognostic	scores	(BCLC,	Child‐Pugh).	Consequently,	it	remains	
unknown	whether	 this	new	model	outperforms	 the	existing	models	
and	whether	risk	stratification	of	sorafenib‐treated	patients	might	be	
further	refined	using	data	from	‘real‐life’	patients.
Therefore,	this	study	aimed	to	(1)	validate	the	PROSASH	model	
in	HCC	patients	treated	with	sorafenib	in	daily	clinical	practice	and	
(2)	improve	the	PROSASH	based	on	patients	treated	in	clinical	prac‐
tice.	 Subsequently,	 PROSASH,	 the	 improved	 model	 (PROSASH‐II)	
and	 existing	 prognostic	 models	 were	 compared	 to	 determine	 the	
utility	for	clinicians	to	predict	the	survival	of	these	patients.
2  | MATERIAL S AND METHODS
2.1 | Study population
Patients	 with	 HCC	 treated	 with	 sorafenib	 were	 recruited	 consecu‐
tively	 at	 five	 tertiary	 European	 centres	 with	 specialist	 multidiscipli‐
nary	services	for	HCC	management:	Bordeaux	 (n	=	306)	and	Rennes	
(n	=	129),	France;	Freiburg	(n	=	183),	Germany;	Amsterdam	(n	=	156)	and	
Rotterdam	(n	=	167),	the	Netherlands.	The	data	were	collected	after	ob‐
taining	the	relevant	authorization	from	the	institutional	review	boards	
and	this	retrospective	study	was	performed	under	ethically	approved	
protocols	(REC	reference	12/LO/1088	and	W17_420#17.488).	Patients	
were	diagnosed	with	HCC	by	histological	or	radiological	criteria	in	ac‐
cordance with international guidelines.6,29	 Exclusion	 criteria	 included	
patients	receiving	combination	treatments	(ie	selective	internal	radia‐
tion	therapy	[SIRT]	with	sorafenib)	or	those	with	an	Eastern	Cooperative	
Oncology	Group	performance	status	(ECOG	PS)	>2.	Patients	received	
sorafenib	with	a	target	dose	of	400	mg	BID,	with	toxicity‐adjusted	dos‐
ing	and	patient	management	according	to	the	local	practice.
2.2 | Data collection and outcomes
Commonly	 available	 clinical,	 imaging	 and	 serum	 variables	 prior	 to	
sorafenib	 treatment	 were	 collected	 by	 members	 of	 the	 research	
team.	Imaging	parameters	were	obtained	from	the	most	recent	radi‐
ological	imaging	prior	to	first	dose	of	sorafenib.	Radiological	staging	
included	 a	 multiphasic	 contrast‐enhanced	 computed	 tomography	
(CT)	or	dynamic	magnetic	 resonance	 imaging	 (MRI).	The	main	out‐
come	measure,	OS,	was	defined	from	the	date	of	start	of	treatment	
to	date	of	death	or	censored	on	the	date	of	last	follow‐up.
Patients	were	staged	according	to	the	PROSASH	model.21 To as‐
sess	whether	improved	prediction	may	be	possible	using	data	from	
daily	practice,	a	new	model	was	built	and	validated	(PROSASH‐II,	de‐
tailed	below).	The	utility	of	both	models	was	compared	with	existing	
prognostic	scores	that	could	be	assessed	in	the	dataset,	including	the	
BCLC	 staging	 system,	 Child‐Pugh	 classification,	 albumin‐bilirubin	
(ALBI)	grade,30	Japan	Integrated	Staging	(JIS)	score,31	hepatoma	ar‐
terial‐embolization	prognostic	(HAP)32	and	the	Sorafenib	Advanced	
HCC	Prognostic	 (SAP)	 score.18	With	 the	exception	of	BCLC	 stage	
and	 Child‐Pugh	 classification,	 which	 are	 commonly	 used	 in	 daily	
practice	and	were	coded	by	the	individual	investigators,	all	prognos‐
tic scores were calculated using the raw data.
2.3 | Statistical methods
Continuous variables were described as means with standard de‐
viation	 (SD)	 or	 medians	 with	 interquartile	 range	 in	 case	 of	 highly	
skewed	distributions.	Categorical	variables	were	described	as	abso‐
lute	and	relative	frequencies.	The	Kaplan‐Meier	method	was	used	to	
generate	and	compare	survival	curves,	and	to	estimate	median	OS	
with	95%	confidence	interval	(95%	CI).	For	all	analyses,	a	two‐tailed	
P	 <	 .05	was	 considered	 statistically	 significant.	 Statistical	 analysis	
was	performed	using	SPSS	Statistics	for	Windows	Version	24.0	(IBM	
Corp)	and	STATA/SE	14.1	(StataCorp).
2.3.1 | Model building, testing and 
external validation
For	the	building	of	a	prognostic	model	from	patients	treated	in	daily	
practice,	the	data	of	four	centres	were	clustered	into	a	training	data‐
set	 and	 the	 largest	 independent	 dataset	 (Bordeaux)	 was	 used	 as	
an	external	validation	set.	Baseline	variables	 that	were	considered	
clinically relevant and available in both datasets were included in 
the	model	building	process	(Table	S1).	Highly	skewed	variables	were	
log‐transformed.	BCLC	stage	and	Child‐Pugh	grade	were	excluded	
from	the	model	building	process	owing	to	multicollinearity	with	fac‐
tors	used	in	these	scoring	systems.	Multiple	imputations	(10x)	using	
chained	equations	were	performed	to	account	 for	missing	key	pa‐
rameters that were missing at random in the training dataset.33,34 
Model	performance,	 derived	 coefficients	 and	P	 values	of	 imputed	
data	were	compared	with	complete	case	data.
In	the	training	set,	the	association	between	OS	and	baseline	vari‐
ables	was	assessed	in	an	exploratory	univariable	and	subsequent	mul‐
tivariable	flexible	parametric	survival	analysis.35‐37	The	advantages	of	
a	flexible	parametric	analysis	over	the	more	commonly	used	Cox	pro‐
portional	hazard	analysis	were	previously	described.21,37	Risk	factors	
were	 reported	with	 hazard	 ratio	 (HR)	 and	 corresponding	P values. 
The	multivariable	model	was	 built	 using	 a	 stepwise	 forward	 selec‐
tion	procedure	of	variables	significant	at	the	5%	level.	The	model	was	
reported	according	to	the	TRIPOD	guidelines38	as	well	as	tested,	op‐
timized and validated using the methods described by Royston and 
Altman.39	 Any	 time‐dependent	 effects	 and	 potential	 proportional	
hazard	violations	by	variables	in	the	model	were	examined	using	the	
likelihood	ratio	(LR)	test.37	The	LR	test	was	also	used	to	optimize	the	
degrees	of	freedom	(number	of	knots)	for	the	restricted	cubic	spline	
function.37	Lastly,	Martingale	residuals	were	plotted	against	continu‐
ous	variables	to	check	the	functional	form	and	non‐linearity.
A	 linear	 predictor	 was	 derived	 using	 the	 coefficients	 of	 the	
model	 variables.	 Four	 risk	 groups	were	generated	by	 applying	 the	
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previously	suggested	cut‐offs	at	the	16th,	50th	and	84th	centiles	of	
the	training	set's	linear	predictor.39 The model, including the linear 
predictor	and	the	centile‐based	risk	group	stratification,	was	applied	
to	the	external	validation	set.
The	 calibration	 of	 survival	 prediction	was	 visually	 assessed	 by	
comparing	the	similarity	between	the	observed	and	predicted	sur‐
vival curves in both the training and validation set. The observed and 
predicted	 survival‐percentage	 at	 12	months	 were	 also	 compared.	
Model	discrimination	was	visually	inspected	by	examining	the	sep‐
aration	survival	curves	of	the	four	risk	groups.	In	addition,	survival	
rates	between	the	risk	groups	were	compared	using	HRs	or	log‐rank	
test	and	the	accompanying	P	values.	Lastly,	subgroup	analyses	of	the	
new	model	were	performed	in	patients	with	Child‐Pugh	A	or	Child‐
Pugh	 B	 because	 current	 guidelines	 recommend	 selecting	 patients	
with	Child‐Pugh	A	patients	only.6,29
2.3.2 | Model comparison
The	PROSASH	model	incorporates	the	variable	‘aspartate	transami‐
nase	 (AST)’	 which	 was	 not	 available	 in	 the	 Rennes	 (training)	 and	
Bordeaux	(validation)	datasets.	Therefore,	model	comparisons	were	
performed	in	three	subgroups	of	patients:
1.	 The	 imputed	 training	 dataset,
2.	 The	external	validation	set,	with	complete	data	for	all	prognostic	
models	except	for	the	PROSASH	model	and.
3.	 Patients	with	complete	data	for	all	prognostic	scores.
For	each	prognostic	model,	the	utility	and	discriminative	performance	
was	quantified	using	the	Akaike	Information	Criterion	(AIC)	Harrell's	C‐
index	and	Royston‐Sauerbrei's	R2D
40,41 A lower AIC indicates a better 
goodness	of	fit,	whereas	a	higher	Harrell's	C‐index	indicates	a	larger	pro‐
portion	of	patient	pairs	has	agreement	between	the	survival	prediction	
and	observed	survival	outcome	in	terms	of	rank.	A	higher	R2D	reflects	a	
better	explained	variation	on	the	log	relative	hazard	scale.	Most	prognos‐
tic	models	consist	of	a	linear	predictor	or	point‐based	system	with	a	risk	
group	categorization	which	can	lead	to	loss	of	information	(ie	ALBI‐score	
and	ALBI	grade	1,	2	and	3).	To	assess	the	difference,	the	performance	of	
each	model	as	a	linear	predictor	or	points	and	risk	groups	was	assessed.	
Because	of	lacking	data,	the	number	of	Child‐Pugh	points	could	not	be	
calculated,	thus	only	the	Child‐Pugh	classes	(A,	B	and	C)	were	assessed.
3  | RESULTS
3.1 | Study population
In	total,	941	patients	who	received	sorafenib	for	advanced	HCC	be‐
tween	February	 2003	 and	December	2016	were	 identified	 for	 this	
study.	Of	these,	21	patients	(2%)	were	excluded	because	they	received	
a	combination	of	 sorafenib	with	 loco‐regional	 treatment	 (n	=	20)	or	
due	an	ECOG	PS	>2	(n	=	1).	Subsequently,	920	patients	were	included	
in	this	study,	of	whom	615	(67%)	patients	were	included	in	the	training	
cohort	and	305	patients	(33%)	in	the	external	validation	cohort.	The	
baseline	 characteristics	 of	 both	 cohorts	 are	 summarized	 in	Table	1.	
Both	cohorts	had	similar	baseline	 features	except	 that	 in	 the	exter‐
nal	 validation	 cohort,	more	 patients	 had	 ECOG	PS	 0	 (65%	 vs	 45%,	
P	<	.001)	and	alcohol‐induced	liver	disease	was	more	common	(64%	
vs 35%, P	<	.001)	compared	with	the	training	cohort,	respectively.	The	
median	OS	was	8.3	months	(95%	CI	7.6‐9.2)	in	all	patients.	There	was	
no	statistically	significant	difference	in	survival	between	the	training	
and	validation	cohort	(HR	1.05,	95%	0.91‐1.21,	P	=	.128;	Figure	S1).
3.2 | Validation of the PROSASH model in routine 
clinical practice
The	PROSASH	model	could	be	applied	to	445/615	(73%)	of	patients	
from	the	training	set	who	had	a	median	OS	of	8.0	months	(95%	CI	
6.7‐9.1).	None	of	the	patients	from	the	external	validation	set	were	
available	 owing	 to	missing	 AST	 (Table	 S1).	With	 the	 exception	 of	
risk	 group	 2	 vs	 1	 (HR	1.35,	 0.94‐1.92,	P	 =	 .102),	 there	were	 clear	
survival	differences	between	the	four	risk	groups	with	a	median	OS	
ranging	from	16.9	to	4.6	months	 (Figure	1)	 in	 risk	groups	1	and	4,	
respectively.
3.3 | Prognostic factors and improved model: 
PROSASH‐II
First,	multiple	imputation	was	performed	on	the	training	set	to	ac‐
count	for	missing	data	(Table	S1).	An	exploratory	univariable	analysis	
showed	 that	 albumin,	 Ln(bilirubin),	 ECOG	PS,	macrovascular	 inva‐
sion,	 extrahepatic	 spread,	 largest	 tumour	 size,	 number	 of	 liver	 le‐
sions,	Ln(AFP)	and	receiving	prior	HCC	treatments	were	associated	
with	OS	(Table	S2).
The	 stepwise	 multivariable	 regression	 identified	 albumin,	
Ln(bilirubin),	 macrovascular	 invasion,	 extrahepatic	 spread,	 largest	
tumour	 size	 and	Ln(AFP)	 as	 statistically	 significant	prognostic	 fac‐
tors	 (Table	 2).	 These	 six	 baseline	 variables	 and	 their	 coefficients	
were	incorporated	in	a	multivariable	model,	named	the	PROSASH‐II	
(Prediction	Of	Survival	in	Advanced	Sorafenib‐treated	HCC	v2):
Linear	predictor: (−0.0337	×	albumin	in	g/L) +
(0.315	×	Ln(bilirubin	in	µmol/L)) +
(0.295	×	macrovascular	invasion,	
where	0	=	No	and	1	=	Yes)
+
(0.181	×	extrahepatic	spread,	
where	0	=	No	and	1	=	Yes)
+
(0.0336	×	Largest	tumour	size	
in	cm)
+
(0.0703	×	Ln(AFP	U/L))  
A	comparison	of	the	model	variables	using	complete	case	data	
(Table	 S3)	 and	 imputed	 data	 showed	 very	 similar	 coefficients	 and	
P	values,	indicating	that	the	model	was	not	greatly	impacted	by	the	
imputation	of	missing	data.
Using	 the	 centile‐based	 cut‐points,	 four	 risk	 groups	were	 cre‐
ated:	 ≤−0.0760	 (risk	 group	 1),	 >−0.0760	 to	 ≤0.355	 (risk	 group	 2),	
>0.355	to	≤0.858	(risk	group	3)	and	>0.858	(risk	group	4).
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TA B L E  1  Baseline	characteristics
Variables
Entire cohort Training‐set External validation
P valuen = 920 n = 615 n = 305
Demographics
Age,	y	(SD) 65	(10.5) 64	(10.8) 66	(9.5) .003
Male	sex	(%) 787	(86) 512	(83) 275	(90) .005
Liver	disease
Aetiology	(%,	multiple	possible)
HBV 94	(10) 77	(13) 17	(6) .001
HCV 153	(17) 86	(14) 67	(22) .002
Alcohol 407	(44) 213	(35) 194	(64) <.001
Unknown/Other 407	(44) 263	(43) 64	(21) <.001
Child‐Pugh	class	(%)
A 747	(85) 507	(87) 240	(79) <.001
B 133	(15) 73	(13) 60	(20)  
C 4	(<1) 0	(0) 4	(1)  
Tumour	parameters
ECOG	PS	(%)
0 477	(52) 279	(45) 198	(65) <.001
1 388	(42) 294	(48) 94	(31)  
2 55	(6) 42	(7) 13	(4)  
Number	of	liver	lesions	(%)
1 229	(25) 135	(22) 94	(32) <.001
2‐3 205	(23) 169	(28) 36	(12)  
>3 468	(52) >3	(50) 163	(56)  
Largest	tumour	size,	mm	(IQR) 65	(37‐100) 65	(37‐100) 64	(36‐100) .593
Macrovascular	invasion	(%) 348	(38) 223	(36) 125	(41) .170
Extrahepatic	spread	(%) 418	(46) 305	(50) 113	(37) <.001
BCLC	stage	(%)
A 9	(1) 5	(1) 4	(1) .032
B 220	(24) 155	(25) 65	(21)  
C 684	(74) 453	(74) 231	(76)  
D 6	(<1) 1	(<1) 5	(2)  
Prior	treatments	(%)
Yes,	received	prior	treatment 467	(51) 308	(50) 159	(52) .558
No,	sorafenib	was	first	treatment 453	(49) 307	(50) 146	(48)  
Serum	tests
AFP,	ng/mL	(IQR) 141	(8‐2574) 127	(10‐2005) 184	(7‐4500) .239
Albumin,	g/L	(SD) 37	(5.7) 38	(5.3) 35	(5.8) <.001
Bilirubin,	µmol/L	(IQR) 15	(10‐24) 15	(10‐22) 17	(12‐28) <.001
AST,	U/L	(IQR) 67	(107) 67	(107) N/A N/A
Creatinine,	µmol/l	(IQR) 73	(61‐88) 75	(62‐90) 69	(58‐81) <.001
Survival	outcomes
Death	(%) 832	(90) 559	(91) 273	(90) .501
Overall	Survival,	months	(95%	CI) 8.3	(7.6‐9.2) 8.9	(8.0‐9.8) 7.7	(6.8‐8.8) .534
Abbreviations:	95%	CI,	95%	confidence	interval;	AFP,	Alpha‐Foetoprotein;	AST,	aspartate	transaminase;	BCLC,	Barcelona	Clinic	Liver	Cancer;	ECOG	
PS,	Eastern	Cooperative	Oncology	Group	performance	status;	HBV,	hepatitis	B	virus;	HCV,	hepatitis	C	virus;	IQR,	interquartile	range;	SD,	standard	
deviation.
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To	simplify	individual	survival	prediction,	the	calculation	for	the	
linear	predictor	and	risk	groups	was	incorporated	in	an	online	cal‐
culator	 (https	://jscalc.io/calc/qXgkZ	NB1h6	B1jEfq).	 This	 calculator	
can	be	used	to	determine	the	risk	group	and	chance	of	survival	at	3,	
6,	12	and	24	months	for	each	patient.	For	example,	a	patient	with	
an	albumin	of	45	g/L,	a	bilirubin	of	7	µmol/L,	an	AFP	of	5789	U/L,	
the largest tumour measuring 5.9 cm with macrovascular invasion, 
but	without	extrahepatic	spread,	will	have	a	predicted	survival	of	
87%, 70%, 44% and 19% and 9% at 3, 6, 12, 24 and 36 months, 
respectively.	 The	 equations	 for	 these	 predictions	 are	 detailed	 in	
Appendix	S1.
3.4 | PROSASH‐II performance in training and 
validation set
There	were	clear	and	statistically	significant	survival	differences	be‐
tween	the	PROSASH‐II	risk	groups	in	the	training	set	(Figure	2A),	with	
a	median	OS	ranging	from	19.6	months	(risk	group	1)	to	3.9	months	
(risk	group	4).	The	PROSASH‐II	model	could	be	applied	to	292	(93%)	
patients	from	the	validation	set.	With	the	exception	of	risk	group	1,	
which	had	fewer	patients	(n	=	36,	12%)	and	showed	overlap	in	95%	CI	
with	risk	group	2	(HR	1.32,	95%	CI	0.85‐2.05,	P	=	.220),	the	risk	groups	
showed	evenly	good	discrimination	in	the	validation	set	(Figure	2B).
Indicated	by	the	concordance	in	the	observed	and	predicted	survival	
curves	of	both	the	training	and	validation	sets	(Figure	3A,B),	the	model	
showed	good	overall	calibration.	Similarly,	the	predicted	and	observed	
median	OS	and	survival	at	12	months	closely	matched	in	both	datasets	
(Table	3).	Although	 the	model	 slightly	 underestimated	 the	OS	of	 risk	
group	1	in	the	training	set,	this	was	not	the	case	in	the	validation	set.
Given	the	similarities	of	baseline	characteristics	and	model	perfor‐
mance	in	the	training	and	validation	sets,	all	patients	were	clustered	
together	and	then	model‐based	stratification	was	re‐applied.	The	me‐
dian	OS	was	19.0,	11.2,	7.2	and	3.4	months	with	a	12‐month	survival	of	
65.6%,	45.6%,	31.2%	and	10.1%,	in	risk	groups	1‐4,	respectively.	There	
was	no	overlap	in	hazard	ratios	(Table	3),	 indicating	good	discrimina‐
tion.	Similar	to	the	training	set,	there	was	a	trend	towards	a	slight	sur‐
vival	underestimation	of	patients	in	risk	group	1	(Figure	4);	however,	
overall,	the	predicted	and	observed	survival	were	closely	matched.
3.5 | Subgroup analysis according to Child‐
Pugh class
In	a	subgroup	analysis	of	Child‐Pugh	A	patients	(n	=	767),	who	had	
a	median	OS	of	9.1	months,	 there	were	clear	 survival	differences	
F I G U R E  1   Overall survival according 
to	the	PROSASH	risk	groups	with	95%	
confidence	intervals
Group N
Median OS, mo
(95% CI)
Hazard ratio 
(95% CI)
P-value
Risk group 1 42 16.9 (13.4-20.0) 1 Reference
Risk group 2 154 10.4 (8.4-11.8) 1.35 (0.94-1.92) .102
Risk group 3 176 6.7 (5.9-8.4) 2.16 (1.52-3.07) <.001
Risk group 4 73 4.6 (3.0-5.6) 3.20 (2.15-4.77) <.001
TA B L E  2  Multivariable	flexible	parametric	regression	on	
imputed	training	set	data
Variables Hazard ratio (95% CI) P‐value
Albumin	–	(g/L) 0.967	(0.951‐0.983) <.001
Ln(Bilirubin)	–	µmol/L) 1.370	(1.178‐1.594) <.001
Macrovascular	invasion	vs	
none
1.342	(1.124‐1.603) .001
Extrahepatic	spread	vs	none 1.198	(1.010‐1.420) .038
Largest	tumour	size	–	cm 1.034	(1.016‐1.052) <.001
LnAFP	–	U/L 1.073	(1.045‐1.101) <.001
Flexible parametric spline functions
γ0	(constant) 2.317	×	10
−2 
(0.916	×	10−2 to 
5.858	×	10−2)
<.001
γ1 5.654	(4.274‐7.479) <.001
γ2 1.034	(1.019‐1.050) <.001
Note: Based	on	one	interior	knot	with	two	degrees	of	freedom.
Abbreviations:	95%	CI,	95%	confidence	interval;	AFP,	Alpha‐
Foetoprotein;	LN,	natural	logarithm.
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between	 the	 various	 PROSASH‐II	 risk	 groups	 (Figure	 S2A).	 The	
median	OS	was	19.0,	10.8,	7.6	and	4.5	months	across	 risk	groups	
1‐4,	respectively.	For	the	subgroup	analysis	of	patients	with	Child‐
Pugh	B	liver	function,	136	patients	were	available	with	a	median	OS	
of	4.3	months	(Figure	S2B).	None	of	these	patients	were	assigned	
to	 risk	 group	1	 and	only	10	 (13.4%)	 to	 risk	 group	2.	 There	was	 a	
trend	 towards	 a	 poorer	 survival	 across	 risk	 groups	 2	 to	 4	with	 a	
median	OS	of	13.4,	5.4	and	3.1	months,	respectively.	The	difference	
between	 risk	groups	2	and	3	was	not	 significant	owing	 to	 limited	
patient	numbers	(HR	1.98,	0.97‐4.04,	P	=	.062).	There	were	statisti‐
cally	 significant	 survival	differences	between	 risk	groups	3	and	4	
(log‐rank	P	=	.002).
3.6 | PROSASH‐II model 
performance and comparison
The	performance	of	the	different	prognostic	models	was	compared	
and	summarized	in	Tables	4	and	5.	Comparisons	were	performed	in	
the	training	set	with	imputed	missing	data	(n	=	615),	the	validation	
set	with	 complete	 data	 (n	 =	 290)	 and	 a	 subgroup	of	 438	patients	
with	 complete	 data	 for	 all	 prognostic	 models.	 Across	 the	 various	
prognostic	models,	 there	was	 a	 slight	 loss	 in	discriminative	power	
when	patients	were	categorized	in	risk	groups	or	prognostic	classes.	
Moreover,	there	was	a	trend	towards	a	higher	C‐index	and	R2D and 
lower	AIC	across	all	assessed	prognostic	models	in	the	validation	set	
compared	with	the	training	set.	In	all	different	subsets,	the	models	
with	the	lowest	predictive	performance	in	terms	of	AIC,	C‐index	and	
R2D	were	 the	BCLC,	Child‐Pugh	 and	 JIS.	 The	HAP	 and	 SAP	 score	
performed	very	similarly	in	the	different	subsets.
In	the	training	set,	the	higher	C‐index	(0.65,	IQR	0.64‐0.65)	and	
R2D	(0.12,	95%	CI	0.08‐0.17)	of	the	PROSASH‐II	indicated	improved	
discriminative	performance	and	explained	variation	compared	with	
the	 currently	 available	 models.	 Likewise,	 the	 PROSASH‐II	 had	 a	
lower	AIC	(1684)	which	indicated	a	better	goodness	of	fit.
In	 the	 validation	 set,	 the	 PROSASH‐II	 model	 had	 a	 higher	 C‐
index	(0.68,	95%	CI	0.65‐0.72)	and	lower	AIC	(828)	than	commonly	
used	scores	 such	as	BCLC	and	Child‐Pugh.	 It	 also	had	 the	highest	
R2D	 (0.16,	95%	CI	0.08‐0.24)	of	all	tested	models,	reflecting	better	
explained	variation.	However,	 the	model	 appeared	 to	have	a	 simi‐
lar	prognostic	performance	as	 the	HAP	and	SAP	scores,	 the	 latter	
showing	a	slightly	higher	C‐index	(0.69,	95%	CI	0.66‐0.72)	and	lower	
AIC	(817)	than	the	PROSASH‐II	model.
F I G U R E  2  Overall	survival	according	to	the	PROSASH‐II	risk	
groups	in	the	training	(A)	and	validation	(B)	set	with	95%	confidence	
intervals
F I G U R E  3  Calibration	plot	of	the	predicted	(dotted	line)	and	
observed	(solid	line)	of	the	overall	survival	according	to	PROSASH‐
II	risk	groups	in	the	training	(A)	and	validation	(B)	set
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In	 the	 complete	 case	 subset	 for	 all	 models	 (n	 =	 438),	 the	
PROSASH‐II	model	had	the	highest	C‐index	(0.63,	95%	CI	0.60‐0.66)	
and R2D	(0.10,	95%	CI	0.06‐0.15)	and	lowest	AIC	(1260).	The	slightly	
poorer	values	for	AIC	(1278),	C‐index	(0.62,	95%	CI	0.59‐0.65)	and	
R2D	 (0.07,	95%	CI	0.04‐0.11)	of	 the	original	PROSASH	model	 indi‐
cated	a	comparable	predictive	performance.
4  | DISCUSSION
In	this	large	multicentre	study	of	patients	treated	with	sorafenib	for	
HCC,	the	clinical	trial‐based	PROSASH	model	was	successfully	vali‐
dated	and	optimized	 (PROSASH‐II)	 in	 routine	clinical	practice.	The	
PROSASH‐II	model,	which	 uses	 fewer	 and	more	objective	 param‐
eters	and	performed	at	least	as	good	as	PROSASH,	offers	individual‐
ized	 survival	 prediction	and	performs	better	 than	 frequently	used	
prognostic	models	(ie	BCLC	and	Child‐Pugh).
In	light	of	the	modest	survival	benefit	 (2‐3	months)	and	signifi‐
cant	costs	and	toxicity	of	sorafenib	in	advanced	HCC,	various	studies	
have	raised	concerns	on	the	cost‐effectiveness	of	sorafenib	in	daily	
practice.42‐44	The	BCLC	staging	system	and	Child‐Pugh	score	are	the	
most	used	prognostic	models,	but	they	have	clear	limitations:	Child‐
Pugh	incorporates	subjective	parameters	which	can	lead	to	misclas‐
sification	 and	 inter‐observer	 variability,9	 whereas	 the	 prognostic	
value	of	BCLC	staging	for	patients	treated	with	the	same	modality	
is	 low.	To	optimize	cost‐effectiveness	and	aid	clinicians	 in	 survival	
prediction	 and	 clinical	 decision‐making,	 several	 other	 prognostic	
models	 have	 been	 proposed	 to	 stratify	 these	 patients	 (Table	 6).	
Interestingly,	most	 of	 these	models	were	 not	 specifically	 built	 for	
sorafenib‐treated	HCC	patients	and	none	of	them	performed	opti‐
mal.9,18,19,45‐47	Lack	of	consensus,	easy	applicability	and	external	val‐
idation	have	hampered	 implementation	of	 these	prognostic	scores	
in	clinical	practice.
We	 were	 able	 to	 compare	 eight	 different	 prognostic	 models:	
ALBI,	 Child‐Pugh,	 BCLC,	HAP,	 SAP,	 JIS,	 PROSASH	 and	 the	 newly	T
A
B
L
E
 3
 
P
re
di
ct
ed
	v
s	
ob
se
rv
ed
	s
ur
vi
va
l	o
f	r
is
k	
gr
ou
ps
	o
f	t
he
	P
R
O
SA
SH
‐I
I	m
od
el
 
Ri
sk
 c
at
.
N
O
bs
er
ve
d
m
O
S 
(9
5%
 C
I)
Pr
ed
ic
te
d
m
O
S 
(9
5%
 C
I)
O
bs
er
ve
d 
%
 s
ur
vi
va
l a
t 1
2 
m
o.
 (9
5%
 C
I)
Pr
ed
ic
te
d 
%
 s
ur
vi
va
l a
t 1
2 
m
o.
 (9
5%
 C
I)
H
az
ar
d 
ra
tio
(9
5%
 C
I)
P 
va
lu
e
Tr
ai
ni
ng
	(n
	=
	6
15
)
1
98
19
.6
	(1
6.
1‐
23
.1
)
16
.4
	(1
4.
5‐
19
.5
)
68
.6
	(5
8.
3‐
76
.9
)
61
.3
	(5
6.
6‐
66
.4
)
1
R
ef
er
en
ce
2
21
0
10
.6
	(9
.5
‐1
2.
7)
10
.8
	(9
.8
‐1
2.
1)
45
.0
	(3
8.
1‐
51
.7
)
45
.5
	(4
1.
8‐
49
.5
)
1.
49
	(1
.1
5‐
1.
93
)
.0
03
3
20
9
7.
0	
(5
.9
‐8
.8
)
7.
5	
(6
.7
‐8
.1
)
29
.3
	(2
3.
2‐
35
.7
)
29
.3
	(2
6.
1‐
32
.9
)
2.
4
0	
(1
.8
5‐
3.
12
)
<.
0
01
4
98
3.
9	
(3
.3
‐5
.0
)
4.
7	
(4
.0
‐5
.6
)
11
.2
	(6
.4
‐1
9.
3)
14
.4
	(1
0.
9‐
18
.9
)
4.
24
	(3
.1
3‐
5.
74
)
<.
0
01
V
al
id
at
io
n	
(n
	=
	2
92
)a
1
36
14
.7
	(9
.2
‐2
4.
7)
16
.6
	(1
3.
0
‐1
8.
5)
57
.4
	(3
9.
5‐
71
.7
)
58
.3
	(5
3.
6‐
63
.4
)
1
R
ef
er
en
ce
2
72
11
.5
	(9
.1
‐1
5.
1)
10
.8
	(9
.8
‐1
2.
0)
47
.3
	(3
5.
3‐
58
.4
)
45
.8
	(4
2.
0
‐4
9.
8)
1.
32
	(0
.8
5‐
2.
05
)
.2
20
3
10
5
7.
2	
(6
.0
‐8
.9
)
7.
2	
(6
.6
‐7
.8
)
34
.9
	(2
5.
9‐
4
4.
0)
28
.8
	(2
5.
6‐
32
.4
)
1.
73
	(1
.1
4‐
2.
63
)
.0
10
4
79
3.
0	
(2
.2
‐3
.8
)
4.
3	
(3
.8
‐4
.9
)
7.
9	
(3
.2
‐1
5.
2)
8.
6	
(6
.1
‐1
2.
1)
4.
8
4	
(3
.1
1‐
7.
54
)
<.
0
01
A
ll	
(n
	=
	9
07
)
1
13
4
19
.0
	(1
4.
7‐
22
.8
)
16
.2
	(1
4.
1‐
19
.0
)
65
.6
	(5
6.
8‐
73
.0
)
60
.8
	(5
6.
1‐
65
.9
)
1
R
ef
er
en
ce
2
28
2
11
.2
	(9
.7
‐1
2.
5)
10
.8
	(9
.8
‐1
2.
0)
45
.6
	(3
9.
6‐
51
.4
)
45
.8
	(4
2.
1‐
49
.8
)
1.
4
4	
(1
.1
5‐
1.
8
0)
.0
01
3
31
4
7.
2	
(6
.2
‐8
.3
)
7.
3	
(6
.7
‐8
.1
)
31
.2
	(2
6.
1‐
36
.4
)
29
.4
	(2
6.
4‐
33
.0
)
2.
12
	(1
.7
0
‐2
.6
5)
<.
0
01
4
17
7
3.
4	
(3
.0
‐4
.5
)
4.
5	
(4
.0
‐5
.2
)
10
.1
	(5
.1
‐1
5.
1)
11
.2
	(8
.3
‐1
5.
3)
4.
52
	(3
.5
4‐
5.
78
)
<.
0
01
A
bb
re
vi
at
io
ns
:	9
5%
	C
I,	
95
%
	c
on
fi
de
nc
e	
in
te
rv
al
;	m
o,
	m
on
th
s;
	(m
)O
S,
	(m
ed
ia
n)
	o
ve
ra
ll	
su
rv
iv
al
;	P
R
O
SA
SH
,	P
re
di
ct
io
n	
O
f	S
ur
vi
va
l	i
n	
A
dv
an
ce
d	
So
ra
fe
ni
b‐
tr
ea
te
d	
H
C
C
.
a 1
3/
30
5	
pa
ti
en
ts
	c
ou
ld
	n
ot
	b
e	
cl
as
si
fi
ed
	a
cc
or
di
ng
	t
o	
th
e	
PR
O
SA
SH
‐I
I	m
od
el
	o
w
in
g	
to
	m
is
si
ng
	v
al
ue
s.
	
F I G U R E  4  Calibration	plot	of	the	predicted	(dotted	line)	
and	observed	(solid	line)	of	the	overall	survival	according	to	the	
PROSASH‐II	risk	groups	(1‐4)	in	all	patients
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proposed	PROSASH‐II	model	 (Table	6).	All	 tested	models	 included	
parameters	 for	 liver	 function	 (ie	 albumin,	 bilirubin,	 AST),	 most	 of	
them	included	tumour‐related	parameters	(ie	AFP,	tumour	size,	mac‐
rovascular	invasion)	and	some	included	‘other’	baseline	parameters	
(age,	HCC	aetiology,	ECOG	PS).	Only	a	few	scores	have	incorporated	
predictive	 parameters	 that	were	 associated	with	 increased	 benefit	
of	 sorafenib	over	placebo	 (extrahepatic	 spread,	NLR	and	hepatitis	
C	virus	infection).16	This	may	reflect	the	modest	impact	of	sorafenib	
on	the	natural	history	of	advanced	HCC.	The	well‐known	prognostic	
impact	of	the	severity	of	the	underlying	liver	disease	was	confirmed	
in	this	study,	reflected	by	multivariable	significance	and	incorpora‐
tion	of	albumin	in	the	PROSASH	and	PROSASH‐II	models.	In	accor‐
dance	with	 prior	 studies,9,48,49	 we	 showed	 that	 despite	 using	 less	
parameters,	 ALBI	 has	 a	 better	 discrimination	 than	 the	Child‐Pugh	
classification.
Although	 initially	 developed	 to	 stratify	 HCC	 patients	 treated	
with	TACE,	 the	HAP	score	 showed	 that	 a	 further	 improvement	of	
predictive	accuracy	is	possible	by	combining	liver	function	(albumin,	
bilirubin)	 and	 tumour‐related	 (AFP,	 tumour	 size)	parameters.18 The 
highly	comparable	SAP	score,	which	adds	ECOG	PS,	performed	sim‐
ilarly	in	our	study.	Depending	on	the	subgroup	of	patients,	the	HAP	
and	SAP	scores	performed	slightly	worse	or	similar	to	the	PROSASH	
and	PROSASH‐II	models.	Given	the	overlap	of	four	prognostic	pa‐
rameters	(albumin,	bilirubin,	AFP	and	tumour	size)	which	are	dichot‐
omized	in	the	HAP	and	SAP	scores,	this	is	not	unexpected.	However,	
neither	 the	 SAP	 nor	 HAP	 score	 offer	 individualized	 survival	 pre‐
diction	 and	 do	 not	 incorporate	 predictors	 of	 improved	 sorafenib	
benefit.
Both	 the	 PROSASH	 and	 PROSASH‐II	 models	 offer	 indi‐
vidualized	 survival	 prediction	 and	 propose	 an	 externally	 vali‐
dated	 four‐tier	 subgroup	 classification	 with	 a	 median	 survival	
of	 17‐10‐7‐5	months	 and	 19‐11‐7‐3	months,	 for	 risk	 groups	 1‐4,	
respectively.	The	PROSASH	incorporated	albumin,	AFP,	AST,	cre‐
atinine,	 age,	 extrahepatic	 spread,	macrovascular	 invasion,	 ECOG	
PS	and	disease	aetiology	 (nine	parameters	 in	 total),	whereas	 the	
PROSASH‐II	 incorporated	 albumin,	 AFP,	 extrahepatic	 spread,	
macrovascular	 invasion,	 tumour	 size	 and	 bilirubin	 (six	 parame‐
ters	 in	 total).	 It	 is	 inevitable	 that	different	studies	with	different	
datasets	 lead	 to	 (slightly)	 different	prognostic	models.	However,	
despite	the	different	origins	(clinical	trial	vs	daily	practice),	there	
is	 significant	 overlap	 in	 the	 PROSASH‐I	 and	 ‐II	 variables	 which	
suggests that these variables are stable and clinically relevant. 
As	 pointed	 out	 by	 several	 statistical	 experts,	 there	 is	 no	widely	
agreed	approach	to	build	a	multivariable	prognostic	model	from	a	
TA B L E  4  Comparison	between	of	the	predictive	performance	of	prognostic	models	in	the	training	and	validation	set
Staging system (no. of 
strata)
Imputed training set (n = 615) Complete case validation set (n = 290)
AIC C‐index (IQRb) R2D (95% CI
a) AIC C‐index (95% CIa) R2D (95% CI
a)
PROSASH‐II
Linear	predictor 1684 0.65	(0.64‐0.65) 0.12	(0.08‐0.17) 828 0.68	(0.65‐0.72) 0.16	(0.08‐0.24)
Grouped	(4) 1697 0.64	(0.64‐0.64) 0.12	(0.08‐0.17) 839 0.67	(0.64‐0.70) 0.16	(0.09‐0.25)
PROSASH
Linear	predictor — — — — — —
Grouped	(4) — — — — — —
ALBI
Linear	predictor 1764 0.59	(0.59‐0.59) 0.04	(0.01‐0.06) 867 0.62	(0.58‐0.65) 0.06	(0.03‐0.13)
Grade	(3) 1781 0.56	(0.55‐0.56) 0.03	(<0.01‐0.05) 877 0.58	(0.55‐0.61) 0.05	(0.01‐0.12)
Child‐Pugh	(3) 1782 0.53	(0.53‐0.53) 0.05	(0.01‐0.09) 867 0.58	(0.55‐0.61) 0.11	(0.04‐0.21)
BCLC	(4)c 1785 0.54	(0.52‐0.56) 0.02	(<0.01‐0.06) 885 0.57	(0.55‐0.60) 0.03	(0.01‐0.08)
HAP
Points	(5) 1733 0.60	(0.60‐0.60) 0.08	(0.04‐0.12) 833 0.67	(0.64‐0.70) 0.16	(0.09‐0.25)
Classes	(4) 1738 0.60	(0.60‐0.60) 0.08	(0.04‐0.11) 840 0.66	(0.63‐0.69) 0.14	(0.07‐0.23)
SAP
Points	(5) 1733 0.60	(0.60‐0.61) 0.08	(0.04‐0.12) 817 0.69	(0.66‐0.72) 0.16	(0.09‐0.27)
Classes	(3) 1738 0.59	(0.59‐0.59) 0.09	(0.04‐0.13) 830 0.66	(0.63‐0.69) 0.14	(0.07‐0.23)
JIS	(5) 1775 0.55	(0.55‐0.55) 0.03	(0.01‐0.06) 877 0.59	(0.55‐0.62) 0.05	(0.02‐0.12)
Abbreviations:	95%	CI,	95%	confidence	interval;	AIC,	Akaike	Information	Criterion;	ALBI;	albumin‐bilirubin;	C‐index,	BCLC,	Barcelona	Clinic	Liver	
Cancer;	HAP,	Hepatoma	Arterial‐embolization	Prognostic	score;	Harrell's	C‐index;	JIS,	Japan	Integrated	Staging	score;	R2D,	Royston‐Sauerbrei's	R2D; 
PROSASH,	Prediction	Of	Survival	in	Advanced	Sorafenib‐treated	HCC;	SAP,	Sorafenib	Advanced	HCC	Prognostic	score.
aConfidence	intervals	estimated	from	200	bootstrap	samples.	
bMedian	and	IQR	for	each	model	were	estimated	from	the	10	imputed	linear	predictors.	
cOnly	n	=	1	missing	in	training	cohort,	thus	a	complete	case	analysis	was	performed.	
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set	of	candidate	predictors.50,51	In	this	study,	we	aimed	to	report	
on	the	optimized	statistical	associations	in	daily	clinical	practice	of	
sorafenib‐treated	patients	guided	by	two	main	principles	in	prog‐
nostic	model	building.	Firstly,	the	parameters	should	be	commonly	
available	 in	 centres	 treating	 patients	with	HCC.	 Secondly,	mod‐
els	should	be	widely	validated	and	universally	applicable.	For	this	
purpose,	we	used	 large	 international	 datasets	 that	 have	 inevita‐
ble	differences	in	data	availability.	As	suggested	by	Royston	et	al,	
this	was	handled	by	multiple	imputation	of	randomly	missing	data	
(Table	S1)	and	by	balancing	data	availability	(ie	parameter	selection)	
and	analytic	power	(ie	patient	numbers).50	Using	this	approach,	we	
were	able	 to	build	 the	PROSASH‐II	model	which	 required	 fewer	
and	only	highly	reproducible	parameters	while	 it	performed	bet‐
ter	in	terms	of	C‐index,	AIC	and	R2D	than	its	predecessor.	Disease	
aetiology	and	ECOG	PS	are	less	objective	parameters	which	may	
lead	to	inter‐	and	intra‐user	variability	in	daily	practice,	favouring	
PROSASH‐II	as	a	tool	that	can	aid	clinicians	 in	providing	patient‐
tailored	 treatment.	Moreover,	 PROSASH‐II	was	 built	 and	 tested	
on	a	daily	clinical	practice	population	 in	which	 it	will	be	applied.	
Currently,	guidelines	recommend	to	consider	all	patients	with	well‐
preserved	 liver	 function	 (Child‐Pugh‐A)	 who	 are	 unsuitable	 for	
loco‐regional	therapy	for	sorafenib	treatment.	The	clear	subgroup	
survival	 differences	 of	 PROSASH‐II	 risk	 groups	 in	 Child‐Pugh	 A	
patients	show	that	even	in	‘guideline	concordant	patients’	a	more	
individualized	 decision	 is	 possible.	 Patients	 within	 risk	 group	 3	
(median	OS	7‐8	months)	may	have	more	benefit	from	alternative	
treatments	 (lenvantinib,	 clinical	 trials	 ie	 with	 PD1/PD‐L1	 block‐
ers),	whereas	patients	within	risk	group	4	(median	OS	3‐5	months)	
could	be	counselled	to	receive	best‐supportive	care	only.	A	similar	
stratification	was	seen	in	patients	classified	as	Child‐Pugh	B	who	
are	currently	not	recommended	to	be	treated	with	sorafenib	and	
have	a	poor	prognosis	(median	OS	of	4.3	months).	Still,	a	small	sub‐
group	of	these	patients	(risk	group	2,	<10%)	had	a	better	prognosis	
(risk	group	2,	median	OS	13.4	months)	and	could	be	considered	for	
treatment	with	sorafenib.
In	 addition,	 the	 PROSASH‐II	 stratification	 could	 be	 used	 for	
pre‐planned	or	post‐hoc	subgroup	analyses	of	ongoing	and	final‐
ized	phase‐III	studies	comparing	sorafenib	with	alternative	treat‐
ments.	Another	application	would	be	to	generate	survival	curves	
of	patients	with	advanced	HCC	treated	with	new	agents	in	phases	
I‐II	studies.	A	quantitative	comparison	between	the	observed	sur‐
vival	 outcomes	of	 tested	 agent	 and	 the	predicted	 sorafenib	 sur‐
vival	remains	difficult	in	these	‘in	silico’	clinical	trials,	but	it	could	
aid	in	deciding	whether	these	agents	can	proceed	to	be	tested	in	
a	phase	III	trial.
This	 study	 has	 several	 limitations,	 foremost	 the	 retrospective	
design	 and	 its	 inherent	 limitations.	 Owing	 to	missing	 parameters,	
some	previously	 proposed	prognostic	 factors	 (ie	NLR,16,52‐55 body 
composition13,56)	could	not	be	taken	into	account	and	not	all	previ‐
ously	proposed	models	could	be	 included	in	the	comparison	(CLIP,	
NIACE).	Secondly,	 this	 study	was	performed	 in	patients	 treated	 in	
European	countries	 and	 should	be	validated	 in	other	geographical	
areas	(i.e.	Asia).
Despite	over	a	decade	of	sorafenib	usage	and	extensive	studies,	
no	molecular	markers	with	 a	 strong	 association	with	mechanism	of	
sorafenib	 action	 have	 been	 identified,	 reflecting	 the	 complexity	 of	
advanced	stage	HCC	and	the	difficulty	of	simplifying	this	into	easily	
applicable	biomarkers.8	Our	calculator	provides	a	clinically	applicable	
and	validated	model	for	the	unmet	need	of	outcome	prediction	prior	
to	sorafenib	treatment.	Future	studies	could	improve	the	risk	stratifi‐
cation,	survival	prediction	and	clinical	decision‐making	by	not	only	tak‐
ing	into	account	baseline	factors	(pre‐sorafenib)	but	also	parameters	
that	can	be	monitored	and	may	be	of	potential	prognostic	 influence	
during	treatment	(ie	sorafenib	dose,	dynamics	in	liver	function,	AFP,	
radiological	 response	or	 pattern	of	 progression).	 The	more	 recently	
approved	 second‐line	 treatments	 for	 advanced	HCC	 (ie	 regorafenib	
[2017],	cabozantinib	[2019])	most	 likely	did	not	have	a	major	impact	
on	the	current	model	because	the	included	patients	were	treated	with	
sorafenib	prior	to	FDA/EMEA	approval	of	these	treatments	and	the	
landmark	 trials	 of	 these	 agents	 had	 strict	 inclusion	 criteria.	 Future	
studies	aiming	to	implement	these	variables	into	robust	tools	and	val‐
idated	models	will	require	large	collaborations	with	detailed	and	high‐
quality	(prospective)	datasets.	To	avoid	statistical	bias	(overfitting),	it	
remains	important	to	externally	validate	novel	prognostic	models.
TA B L E  5  Comparison	of	prognostic	models	in	a	complete	case	
population
Staging system (no. 
of strata)
Complete case for all models (n = 438)
AIC C‐index (95% CI*) R2D (95% CI
a)
PROSASH‐II
Linear	predictor 1260 0.63	(0.60‐0.66) 0.10	(0.06‐0.15)
Grouped	(4) 1266 0.62	(0.60‐0.65) 0.10	(0.05‐0.15)
PROSASH
Linear	predictor 1278 0.62	(0.59‐0.65) 0.07	(0.04‐0.11)
Grouped	(4) 1279 0.61	(0.58‐0.64) 0.08	(0.04‐013)
ALBI
Linear	predictor 1303 0.58	(0.55‐0.61) 0.03	(0.01‐0.07)
Grade	(3) 1318 0.54	(0.52‐0.57) 0.02	(<0.01‐0.05)
Child‐Pugh	(3) 1317 0.52	(0.51‐0.54) 0.04	(0.01‐0.07)
BCLC	(4) 1320 0.53	(0.51‐0.56) 0.01	(<0.01‐0.04)
HAP
Points	(5) 1289 0.59	(0.56‐0.62) 0.06	(0.03‐0.11)
Classes	(4) 1292 0.59	(0.56‐0.62) 0.06	(0.03‐0.11)
SAP
Points	(5) 1293 0.59	(0.56‐0.62) 0.05	(0.02‐0.09)
Classes	(3) 1291 0.58	(0.55‐0.61) 0.07	(0.03‐0.13)
JIS	(5) 1315 0.53	(0.51‐0.56) 0.02	(<0.01‐0.05)
Abbreviations:	95%	CI,	95%	confidence	interval;	AIC,	Akaike	
Information	Criterion;	ALBI;	albumin‐bilirubin;	C‐index,	BCLC,	
Barcelona	Clinic	Liver	Cancer;	HAP,	Hepatoma	Arterial‐embolization	
Prognostic	score;	Harrell's	C‐index;	JIS,	Japan	Integrated	Staging	score;	
R2D,	Royston‐Sauerbrei's	R2D;	PROSASH,	Prediction	Of	Survival	in	
Advanced	Sorafenib‐treated	HCC;	SAP,	Sorafenib	Advanced	HCC	
Prognostic	score.
aConfidence	intervals	estimated	from	200	bootstrap	samples.	
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TA B L E  6  Literature	reported	performance	of	prognostic	models	patients	with	HCC	treated	with	sorafenib
Name model
Variables
C‐index Type of cohort (n) ReferencesTumour‐related Liver function Other
Tested in this study
PROSASH‐II AFP
EHS
MVI
Tumour size
Bilirubin
Albumin
 0.65
0.68
Training	(615)
Validation	(290)
Present	study
Present	study
PROSASH AFP
EHS
MVI
AST
Albumin
Aetiology
Age
Creatinine
0.72
0.70
0.62
Training	(500)
Validation	(421)
Validation	(438)
Berhane	et	al21
Berhane	et	al21
Present	study
ALBI  Albumin
Bilirubin
 0.60
0.60
NA
0.59
0.62
Validation	(905)
Validation	(468)
Validation	(681)
Validation	(615)
Validation	(290)
Edeline	et	al9
Edeline	et	al18
Samawi	et	al46
Present	study
Present	study
Child‐Pugh  Albumin
Bilirubin
PT/INR
Ascites
Encephalopathy
 0.61
0.53
0.58
Validation	(905)
Validation	(615)
Validation	(290)
Edeline	et	al9
Present	study
Present	study
BCLC ECOG	PS
EHS
MVI
Child‐Pugh  0.64
0.55
NA
0.54
0.57
Validation	(435)
Validation	(468)
Validation	(681)
Validation	(615)
Validation	(290)
Takeda	et	al19
Edeline	et	al18
Samawi	et	al46
Present	study
Present	study
HAP AFP
Tumour size
Albumin
Bilirubin
 0.65
0.60
0.67
Validation	(468)
Validation	(615)
Validation	(290)
Edeline	et	al18
Present	study
Present	study
SAP ECOG	PS
AFP
Tumour size
Albumin
Bilirubin
 0.64
0.60
0.69
Validation	(468)
Validation	(615)
Validation	(290)
Edeline	et	al18
Present	study
Present	study
JIS Tumour size
Tumour number
MVI
Child‐Pugh  0.69
0.55
0.59
Validation	(435)
Validation	(615)
Validation	(290)
Takeda	et	al19
Present	study
Present	study
Not tested in this study
CLIP AFP
MVI
Tumour number
%	Tumour	extent
Child‐Pugh  0.54
NA
Validation	(435)
Validation	(681)
Takeda	et	al19
Samawi	et	al46
Okuda %	Tumour	extent Albumin
Bilirubin
Ascites
 0.63
NA
Validation	(435)
Validation	(681)
Takeda	et	al19
Samawi	et	al46
JRC AFP
DCP
EHS
MVI
Morphology
Albumin
Bilirubin
 0.76 Training	(435) Takeda	et	al19
NIACE ECOG	PS
AFP
Morphology
Tumour number
Child‐Pugh  NA Validation	(83)
Validation	(83)
Validation	(119)
Adhoute et al17
AJCC	TNM7 Tumour size
Tumour number
MVI
EHS
  NA Validation	(681) Samawi	et	al46
  (Continued)
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In	conclusion,	our	study	validated	the	PROSASH	model	 in	rou‐
tine	daily	practice	and	proposed	an	 improved	model	 (PROSASH‐II)	
which	uses	less	and	more	objective	clinical	features.	The	PROSASH‐
II	model	outperforms	the	currently	available	models	and	offers	risk	
group	stratification	and	individualized	survival	prediction	that	can	be	
used	for	tailored	treatment	of	HCC	in	daily	practice	and	pre‐planned	
subgroups	analyses	of	future	studies.
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